Superluminal Medicines Inc. Secures $120M in Series A Funding to Revolutionize Drug Discovery

We are thrilled to announce that Superluminal Medicines Inc., a pioneering generative biology and chemistry company based in Boston, has successfully raised $120 million in its latest funding round. This substantial investment comes from a formidable group of investors, including RA Capital Management, Insight Partners, NVIDIA, and Gaingels, all of whom share our vision of revolutionizing the speed and accuracy of medicine creation. At Superluminal, we are dedicated to transforming the pharmaceutical landscape through our innovative platform, which harnesses cutting-edge technology to develop candidate-ready compounds with unprecedented speed. By integrating deep biology and chemistry expertise with advanced machine learning and proprietary big data infrastructure, we can accurately model protein shapes and design highly selective compounds that target specific structural changes for therapeutic effects. Our discovery engine, which features leading pharmacokinetic and toxicology in silico prediction capabilities, positions us at the forefront of pharmaceutical research and development. With our lead program candidate on the horizon and our pipeline validated by initial programs targeting high-value GPCRs, we are well on our way to delivering groundbreaking treatments. This funding will enable us to accelerate our research initiatives, expand our talented team, and ultimately bring transformative therapies to patients in need. We are excited about this journey and grateful for the continued support from our investors, as we work towards our mission of ensuring that better medicine is developed, faster.